FDA grants priority review to lumasiran for primary hyperoxaluria type 1

Priority review for this investigational, subcutaneously administered RNA interference therapeutic that targets hydroxyacid oxidase 1 is based on data from the ILLUMINATE-A Phase III clinical trial which was felt to be promising.

Source:

Biospace Inc.